• 四川大學華西醫(yī)院感染性疾病中心 生物治療國家重點實驗室感染性疾病研究室（成都，610041）;

【摘要】 白細胞介素-28B（IL-28B）是一種重要的細胞因子，也被稱之為干擾素-λ3 （IFN-λ3），其作用機制類似于IFN-α，通過誘導受體異二聚體化，活化JAK-STAT信號通路，進而發(fā)揮抗病毒、免疫調(diào)節(jié)等生物學作用。最近國外研究團隊相繼發(fā)現(xiàn)IL-28B基因附近的單核苷酸多態(tài)性與干擾素聯(lián)合利巴韋林治療慢性丙型病毒性肝炎的療效密切相關(guān)。這有助于通過宿主基因水平更準確的預測患者治療效果，并有可能在將來提供一種更有效的治療方案。

引用本文： 徐輝,雷學忠. 白細胞介素-28B附近基因多態(tài)性與慢性丙型肝炎的抗病毒治療相關(guān)性的研究進展. 華西醫(yī)學, 2011, 26(1): 139-141. doi: 復制

1. 　Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009, 49(4): 1335-1374.
2. 　Amin J, Dore GJ, O’connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study[J]. J Hepatol, 2006, 45(2): 197-203.
3. 　Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C[J]. J Viral Hepatitis, 2009, 16(2): 75-90.
4. 　Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C - A randomized study of treatment duration and ribavirin dose[J]. Ann Intern Med, 2004, 140(5): 346-355.
5. 　Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial[J]. Clin Infect Dis, 2008, 47(10): 1260-1269.
6. 　Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection[J]. World J Gastroenterol, 2008, 14(21): 3416-3420.
7. 　Sheppard P, Kindsvogel W, Xu WF, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R[J]. Nat Immunol, 2003, 4(1): 63-68.
8. 　Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex[J]. Nat Immunol, 2003, 4(1): 69-77.
9. 　Ge DL, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J]. Nature, 2009, 461(7262): 399-401.
10. 　Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J]. Nature, 2009, 461(7265): 798-801.
11. 　Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication[J]. J Virol, 2005, 79(6): 3851-3854.
12. 　Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo[J]. J Virol, 2006, 80(9): 4501-4509.
13. 　Marcello T, Grakoui A, Barba-spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics[J]. Gastroenterology, 2006, 131(6): 1887-1898.
14. 　Suppiah V, Moldowan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J]. Nat Genet, 2009, 41(10): 1100-1174.
15. 　Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J]. Na Genet, 2009, 41(10): 1105-1181.
  1. 1. 　Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update[J]. Hepatology, 2009, 49(4): 1335-1374.
  2. 2. 　Amin J, Dore GJ, O’connell DL, et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study[J]. J Hepatol, 2006, 45(2): 197-203.
  3. 3. 　Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C[J]. J Viral Hepatitis, 2009, 16(2): 75-90.
  4. 4. 　Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C - A randomized study of treatment duration and ribavirin dose[J]. Ann Intern Med, 2004, 140(5): 346-355.
  5. 5. 　Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial[J]. Clin Infect Dis, 2008, 47(10): 1260-1269.
  6. 6. 　Yan KK, Guirgis M, Dinh T, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection[J]. World J Gastroenterol, 2008, 14(21): 3416-3420.
  7. 7. 　Sheppard P, Kindsvogel W, Xu WF, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R[J]. Nat Immunol, 2003, 4(1): 63-68.
  8. 8. 　Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambda s mediate antiviral protection through a distinct class II cytokine receptor complex[J]. Nat Immunol, 2003, 4(1): 69-77.
  9. 9. 　Ge DL, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J]. Nature, 2009, 461(7262): 399-401.
  10. 10. 　Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J]. Nature, 2009, 461(7265): 798-801.
  11. 11. 　Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication[J]. J Virol, 2005, 79(6): 3851-3854.
  12. 12. 　Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo[J]. J Virol, 2006, 80(9): 4501-4509.
  13. 13. 　Marcello T, Grakoui A, Barba-spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics[J]. Gastroenterology, 2006, 131(6): 1887-1898.
  14. 14. 　Suppiah V, Moldowan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J]. Nat Genet, 2009, 41(10): 1100-1174.
  15. 15. 　Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J]. Na Genet, 2009, 41(10): 1105-1181.